William Blair analyst Jonathan Ho has maintained their bullish stance on CLBT stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jonathan Ho has given his Buy rating due to a combination of factors that highlight Cellebrite DI’s strong financial performance and promising growth prospects. The company has shown resilience by maintaining steady U.S. federal business during challenging times, such as the government shutdown, and has reiterated its full-year ARR outlook while raising its EBITDA guidance. This demonstrates management’s confidence in the company’s ability to sustain and accelerate revenue growth.
Furthermore, several key drivers are expected to fuel growth in 2026, including the Inseyets upgrade cycle, strong growth of Guardian, anticipated FedRAMP approval, the upcoming Corellium acquisition, and new product contributions. The company’s revenue and adjusted EBITDA have exceeded consensus estimates, reflecting effective cost management and margin expansion. These factors, combined with the strategic leadership of CEO Tom Hogan, suggest significant upside potential for Cellebrite DI’s stock.
Ho covers the Technology sector, focusing on stocks such as Cellebrite DI, Allot, and Palo Alto Networks. According to TipRanks, Ho has an average return of 8.7% and a 50.00% success rate on recommended stocks.
In another report released today, TD Cowen also reiterated a Buy rating on the stock with a $25.00 price target.